NEW YORK, Jan. 19, 2017 /PRNewswire/ -- This report on the opioid induced constipation treatment market studies the current and future scenario of the global market. Large number of chronic pain sufferers is responsible for rising opioid consumption. Severe chronic constipation is a major side effect of consumption of opioid and shows resistance to traditional laxatives. Hence, novel targeted therapy has been prescribed to treat opioid induced constipation. Rising number of OIC sufferers, launch of targeted medicines, and growing awareness about the therapy are the major drivers of the market. The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market. Based on dosage form of the drug, the market has been segmented into three major forms: solid, semi-solid, and liquid. The market segments have been analyzed based on available approved drugs for treatment and their dosage forms, cost-effectiveness, and preference for dosage form by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. Based on drug class, the opioid induced constipation treatment market has been segmented into three major categories based on their mechanism of action: mu opioid receptor antagonist (Movantik and Relistor), chloride channel activator (Amitiza), and others (Resolor and traditional medicines). The market segments have been extensively analyzed based on efficacy, cost, revenue, number of launched drugs, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. Pipeline analysis has also been provided in the report. The market has been estimated for drugs that are in phase III (late stage) clinical trials. Presently, Naldemedine is an under NDA review. A tabular representation has been included for phase II and phase I drugs. Geographically, the global opioid induced constipation treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia Pacific (Australia, Japan, South Korea, and Rest of Asia Pacific), Latin America (Brazil and Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. The report also profiles major players in the global opioid induced constipation treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. The global opioid induced constipation treatment market has been segmented as follows:Global Opioid Induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013–2023 (US$ Mn)SolidSemisolidLiquidGlobal Opioid Induced Constipation Treatment Market Revenue, by Drug Class, 2013–2023 (US$ Mn)mu-opioid receptor antagonistChloride channel activatorOthersGlobal Opioid Induced Constipation Treatment Market Revenue, by Pipeline, 2013–2023 (US$ Mn)Late Stage (phase III) candidates (forecast from the year of approval till 2023) (US$ Mn)NaldemedineOthersEarly Stage (phase II and phase I) candidates (tabular representation)AxelopranOthersGlobal Opioid Induced Constipation Treatment Market Revenue, By Geography, 2013–2023 (US$ Mn)OverviewNorth AmericaU.S.CanadaEuropeU.K.GermanyFranceRest of EuropeAsia PacificAustraliaJapanSouth KoreaRest of Asia PacificLatin AmericaBrazilRest of Latin AmericaRest of the WorldRead the full report: http://www.reportlinker.com/p03999870-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/opioid-induced-constipation-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015---2023-300393980.html
SOURCE Reportlinker
